Clinicopathological Significance of Claspin Overexpression and Its Efficacy As a Novel Biomarker for the Diagnosis of Urothelial Carcinoma

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2021 Nov 29

PMID 34842980

Citations 5

Authors

Go Kobayashi

Tetsutaro Hayashi

Kazuhiro Sentani

Takashi Babasaki

Yohei Sekino

Shogo Inoue

Naohiro Uraoka

Masanori Hanamoto

Hiroyuki Nose

Jun Teishima

Naohide Oue

Akio Matsubara

Naomi Sasaki

Wataru Yasui

Affiliations

Soon will be listed here.

Abstract

We previously reported that claspin is a key regulator in the progression of gastric cancer and renal cell carcinoma. However, the clinicopathological significance of claspin in urothelial carcinoma (UC) has not been investigated. We analyzed the expression and distribution of claspin in UC cases by immunohistochemistry. In the non-neoplastic urothelium, the expression of claspin was either weak or absent, whereas UC tissues showed nuclear staining. The expression of claspin was detected in 58 (42%) of a total of 138 upper tract UC cases treated by radical nephroureterectomy without neoadjuvant chemotherapy. Claspin-positive UC cases were associated with nodular/flat morphology, variant histology, high tumor grade, high pathological T grade, and lymphatic and venous invasion. The expression of claspin was significantly associated with decreased progression-free survival and cancer-specific survival. In addition, claspin was co-expressed with Ki-67, PD-L1, HER2, EGFR, and p53 in consecutive tumor sections of UC. An immunohistochemical analysis of claspin in biopsy specimens revealed that strong to moderate claspin staining was more frequently observed in carcinoma in situ in comparison to dysplasia or the benign urothelium. Furthermore, immunocytochemistry for claspin on urine cytology slides demonstrated that the proportion of claspin-positive cells was significantly greater in high-grade UC than in benign cases. These results suggest that claspin may be a novel prognostic marker and a possible therapeutic target molecule for UC. Moreover, claspin could be a useful diagnostic biomarker of urothelial neoplasia.

Citing Articles

Distribution and clinicopathological characteristics of G-CSF expression in tumor cells and stromal cells in upper tract urothelial carcinoma.

Kobayashi G, Sekino Y, Nakahara H, Kobatake K, Goto K, Hayashi T J Cancer Res Clin Oncol. 2024; 151(1):18.

PMID: 39739128 PMC: 11685250. DOI: 10.1007/s00432-024-06045-1.

Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization.

Hori K, Yamada S, Murata K, Miyata H, Mizue Y, Murai A Hum Vaccin Immunother. 2024; 20(1):2414542.

PMID: 39539024 PMC: 11572277. DOI: 10.1080/21645515.2024.2414542.

MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.

Kobayashi G, Hayashi T, Sentani K, Uraoka N, Fukui T, Kido A Diagn Pathol. 2023; 18(1):106.

PMID: 37737200 PMC: 10515259. DOI: 10.1186/s13000-023-01392-y.

A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers.

Chen Y, Wen H, Li Y, Han Y, Tan J, Guo C Biol Proced Online. 2023; 25(1):16.

PMID: 37268895 PMC: 10239117. DOI: 10.1186/s12575-023-00201-6.

Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.

Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A Cancer Immunol Immunother. 2023; 72(7):2057-2065.

PMID: 36795123 PMC: 10992486. DOI: 10.1007/s00262-023-03388-5.

References

Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M . European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2017; 73(1):111-122. DOI: 10.1016/j.eururo.2017.07.036. View

Leow J, Chong K, Chang S, Bellmunt J . Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open. 2017; 1(6):e000126. PMC: 5419214. DOI: 10.1136/esmoopen-2016-000126. View

Abouassaly R, Alibhai S, Shah N, Timilshina N, Fleshner N, Finelli A . Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. 2010; 76(4):895-901. DOI: 10.1016/j.urology.2010.04.020. View

Jeldres C, Sun M, Isbarn H, Lughezzani G, Budaus L, Alasker A . A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology. 2009; 75(2):315-20. DOI: 10.1016/j.urology.2009.10.004. View

Zangouei A, Barjasteh A, Rahimi H, Mojarrad M, Moghbeli M . Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal. 2020; 18(1):127. PMC: 7427778. DOI: 10.1186/s12964-020-00625-7. View

Siefker-Radtke A, Apolo A, Bivalacqua T, Spiess P, Black P . Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. J Urol. 2017; 199(5):1129-1142. DOI: 10.1016/j.juro.2017.10.041. View

Tripathi A, Plimack E . Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Curr Urol Rep. 2018; 19(12):109. DOI: 10.1007/s11934-018-0851-7. View

Favaretto R, Zequi S, Oliveira R, Santana T, Costa W, Cunha I . Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications. Int Braz J Urol. 2017; 44(1):22-37. PMC: 5815529. DOI: 10.1590/S1677-5538.IBJU.2017.0204. View

Stone L . Immunology: PD-1 and PD-L1 prognostic in UTUC. Nat Rev Urol. 2017; 14(9):518. DOI: 10.1038/nrurol.2017.120. View

10.

Fang D, Xiong G, Li X, Chen X, Zhang L, Yao L . Pattern and risk factors of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a large Chinese center experience. J Formos Med Assoc. 2013; 113(11):820-7. DOI: 10.1016/j.jfma.2013.11.004. View

11.

McKenney J, Desai S, Cohen C, Amin M . Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001; 25(8):1074-8. DOI: 10.1097/00000478-200108000-00013. View

12.

Asgari M, Nabi Maybodi M, Abolhasani M . Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67. Med J Islam Repub Iran. 2016; 30:400. PMC: 5004568. View

13.

Tschirdewahn S, Dorp F . [Diagnostics of nonmuscle-invasive urothelial cell carcinoma of the bladder]. Urologe A. 2015; 54(4):480-3. DOI: 10.1007/s00120-015-3772-9. View

14.

Zhou A, Hutchinson L, Cosar E . Urine Cytopathology and Ancillary Methods. Surg Pathol Clin. 2016; 7(1):77-88. DOI: 10.1016/j.path.2013.10.003. View

15.

Gopalakrishna A, Longo T, Fantony J, Owusu R, Foo W, Dash R . The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient. BMC Urol. 2016; 16(1):30. PMC: 4906712. DOI: 10.1186/s12894-016-0147-5. View

16.

Abdullah L . The value of urine cytology in the diagnosis of bladder cancer. Cytopathological correlation. Saudi Med J. 2013; 34(9):937-41. View

17.

Chang S, Smith E, Levin M, Rao J, Moatamed N . Comparative study of ProEx C immunocytochemistry and UroVysion fluorescent in-situ hybridization assays on urine cytology specimens. Cytojournal. 2015; 12:2. PMC: 4325383. DOI: 10.4103/1742-6413.149845. View

18.

Sullivan P, Nooraie F, Sanchez H, Hirschowitz S, Levin M, Rao P . Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study. Cancer. 2009; 117(3):167-73. DOI: 10.1002/cncy.20026. View

19.

Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E . uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol. 2013; 121(7):392-7. DOI: 10.1002/cncy.21287. View

20.

Dimashkieh H, Wolff D, Smith T, Houser P, Nietert P, Yang J . Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 2013; 121(10):591-7. PMC: 3800248. DOI: 10.1002/cncy.21327. View